Report Phase 3 core data for once-weekly subcutaneous ULTOMIRIS
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 13 Jan 2020
- Due
- 30 Jun 2020
- Delivered
- June 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 core data read-out 2Q2020”
What we found
Evidence strength A What the grades mean
Alexion announced in June 2020 that the Phase 3 study for weekly subcutaneous ULTOMIRIS met its primary objective, fulfilling the commitment to report core data within the second quarter of 2020.
-
A Alexion Pharmaceuticals 10-Q filed 2020-07-30
“In June 2020, Alexion announced that the ongoing study met its primary objective of pharmacokinetic-based non-inferiority of ULTOMIRIS SC versus intravenous (IV) ULTOMIRIS at Day 71.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 core data for once-weekly subcutaneous ULTOMIRIS
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-C899866-019360 · Corrections policy